A recent study using a refined approach (selecting tumor-reactive TILs and combining PD-1 blockade) achieved significant tumor shrinkage in ~24% of heavily pretreated metastatic GI cancer patients (129). This evidence concerns the gene PDCD1 and neoplasm.